These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 15704058)

  • 1. Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study.
    Packer M; McMurray J; Massie BM; Caspi A; Charlon V; Cohen-Solal A; Kiowski W; Kostuk W; Krum H; Levine B; Rizzon P; Soler J; Swedberg K; Anderson S; Demets DL
    J Card Fail; 2005 Feb; 11(1):12-20. PubMed ID: 15704058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Effect of Endothelin Receptor Antagonism With Bosentan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure: Primary Results of the ENABLE Trials.
    Packer M; McMurray JJV; Krum H; Kiowski W; Massie BM; Caspi A; Pratt CM; Petrie MC; DeMets D; Kobrin I; Roux S; Swedberg K;
    JACC Heart Fail; 2017 May; 5(5):317-326. PubMed ID: 28449795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure?
    Kalra PR; Moon JC; Coats AJ
    Int J Cardiol; 2002 Oct; 85(2-3):195-7. PubMed ID: 12208583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure.
    Sütsch G; Kiowski W; Yan XW; Hunziker P; Christen S; Strobel W; Kim JH; Rickenbacher P; Bertel O
    Circulation; 1998 Nov; 98(21):2262-8. PubMed ID: 9826312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute and short-term effects of the nonpeptide endothelin-1 receptor antagonist bosentan in humans.
    Sütsch G; Bertel O; Kiowski W
    Cardiovasc Drugs Ther; 1997 Jan; 10(6):717-25. PubMed ID: 9110115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bosentan and the endothelin system in congestive heart failure.
    Ellahham SH; Charlon V; Abassi Z; Calis KA; Choucair WK
    Clin Cardiol; 2000 Nov; 23(11):803-7. PubMed ID: 11097125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling.
    Mulder P; Richard V; Derumeaux G; Hogie M; Henry JP; Lallemand F; Compagnon P; Macé B; Comoy E; Letac B; Thuillez C
    Circulation; 1997 Sep; 96(6):1976-82. PubMed ID: 9323089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study.
    Galiè N; Beghetti M; Gatzoulis MA; Granton J; Berger RM; Lauer A; Chiossi E; Landzberg M;
    Circulation; 2006 Jul; 114(1):48-54. PubMed ID: 16801459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic endothelin receptor blockade attenuates progressive ventricular dilation and improves cardiac function in rats with myocardial infarction: possible involvement of myocardial endothelin system in ventricular remodeling.
    Fraccarollo D; Hu K; Galuppo P; Gaudron P; Ertl G
    Circulation; 1997 Dec; 96(11):3963-73. PubMed ID: 9403621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bosentan therapy for pulmonary arterial hypertension.
    Rubin LJ; Badesch DB; Barst RJ; Galie N; Black CM; Keogh A; Pulido T; Frost A; Roux S; Leconte I; Landzberg M; Simonneau G
    N Engl J Med; 2002 Mar; 346(12):896-903. PubMed ID: 11907289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update of REACH-1 and MERIT-HF clinical trials in heart failure. Cardio.net Editorial Team.
    Mylona P; Cleland JG
    Eur J Heart Fail; 1999 Jun; 1(2):197-200. PubMed ID: 10937931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of aldosterone secretion in patients with chronic congestive heart failure by endothelins.
    Sütsch G; Bertel O; Rickenbacher P; Clozel M; Yandle TG; Nicholls MG; Kiowski W
    Am J Cardiol; 2000 Apr; 85(8):973-6. PubMed ID: 10760337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.
    Channick RN; Simonneau G; Sitbon O; Robbins IM; Frost A; Tapson VF; Badesch DB; Roux S; Rainisio M; Bodin F; Rubin LJ
    Lancet; 2001 Oct; 358(9288):1119-23. PubMed ID: 11597664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators.
    Krum H; Viskoper RJ; Lacourciere Y; Budde M; Charlon V
    N Engl J Med; 1998 Mar; 338(12):784-90. PubMed ID: 9504938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure.
    Kiowski W; Sütsch G; Hunziker P; Müller P; Kim J; Oechslin E; Schmitt R; Jones R; Bertel O
    Lancet; 1995 Sep; 346(8977):732-6. PubMed ID: 7658874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale and perspective of endothelin-1 antagonism in acute heart failure.
    Kiowski W; Suetsch G; Oechslin E; Schalcher C; Brunner-Larocca HP; Bertel O
    J Cardiovasc Pharmacol; 2001 Nov; 38 Suppl 2():S53-7. PubMed ID: 11811379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of long-term therapy with bosentan on the progression of left ventricular dysfunction and remodeling in dogs with heart failure.
    Mishima T; Tanimura M; Suzuki G; Todor A; Sharov VG; Goldstein S; Sabbah HN
    J Am Coll Cardiol; 2000 Jan; 35(1):222-9. PubMed ID: 10636284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute effects of an endothelin-1 receptor antagonist bosentan at different stages of heart failure in conscious dogs.
    Choussat R; Hittinger L; Barbe F; Maistre G; Carayon A; Crozatier B; Su J
    Cardiovasc Res; 1998 Sep; 39(3):580-8. PubMed ID: 9861300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemodynamic effects of bosentan in patients with chronic heart failure.
    Kiowski W; Sütsch G; Oechslin E; Bertel O
    Heart Fail Rev; 2001 Dec; 6(4):325-34. PubMed ID: 11447307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endothelin antagonism with bosentan: current status and future perspectives.
    Ono K; Matsumori A
    Cardiovasc Drug Rev; 2002; 20(1):1-18. PubMed ID: 12070530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.